In Japanese adults with , produced substantial weight loss across subgroups, with some numerical differences by sex and baseline BMI.
Evidence
This prespecified subgroup analysis of the randomized SURMOUNT-J trial in 225 Japanese adults without diabetes found higher week-72 weight loss and at least 5% weight-loss response rates with tirzepatide 10 mg or 15 mg than placebo across sex, age, and BMI subgroups, with similar safety profiles and cardiometabolic improvement in all subgroups.
Caveat
This was a subgroup analysis with mostly numerical between-subgroup differences, so it was not designed to establish definitive subgroup-specific treatment effects or dosing strategies.
Simplified
AIMS: This analysis aimed to assess the influence of selected baseline factors on treatment response in Japanese patients with .
MATERIALS AND METHODS: This was a prespecified subgroup analysis of the SURMOUNT-J trial. Japanese adults with obesity disease, excluding diabetes, were randomised 1:1:1 to receive once-weekly subcutaneous tirzepatide 10 mg, tirzepatide 15 mg, or placebo. Key safety and efficacy outcomes at week 72 were analysed by baseline characteristics, including sex, age (<65, ≥65 years), and body mass index (BMI; <35 kg/m, ≥35 kg/m). Post hoc analyses were conducted to examine cardiometabolic parameters by subgroup. 2 2
RESULTS: Overall, 225 participants were examined (tirzepatide 10 mg: n = 73; tirzepatide 15 mg: n = 77; placebo: n = 75). Weight reduction at week 72 was generally similar across subgroups. Numerically greater reductions in percent body weight at week 72 were observed in females (estimated treatment differences: 10 mg, -17.5%; 15 mg, -24.9%) compared with males (10 mg, -15.1%; 15 mg, -18.1%) and in the BMI <35 kg/msubgroup (10 mg, -18.7%; 15 mg, -21.7%) compared with the BMI ≥35 kg/msubgroup (10 mg, -11.7%; 15 mg, -20.4%) with tirzepatide compared with placebo. Higher proportions of participants achieved ≥5% weight reduction following week 72 of tirzepatide (86%-100%) compared with placebo (18%-30%) across subgroups, and all subgroups showed improvements in cardiometabolic parameters with tirzepatide. Safety profiles did not substantially differ by subgroup. 2 2
CONCLUSIONS: These results suggest that tailored interventions such as tirzepatide dosage adjustments may help optimise the treatment management of Japanese patients with obesity disease.
STUDY REGISTRATION: ClinicalTrials.gov, NCT04844918.
Key numbers
-17.5%
Weight Reduction Female
Percent body weight reduction at week 72 for 10 mg.
-18.7%
Weight Reduction BMI <35 kg/m
Percent body weight reduction at week 72 for 10 mg.
86%–100%
Achievement of ≥5% Weight Reduction
Proportion of participants achieving at least 5% weight reduction at week 72.
Full Text
We can’t show the full text here under this license.
Koutaro Yokote reports scholarships from Boehringer Ingelheim, Mitsubishi Tanabe Pharma, Sumimoto Pharma, and Takeda; and honoraria from Astellas, Bayer Yakuhin, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly and Company, Kowa Company, Mitsubishi Tanabe Pharma, Novartis, Novo Nordisk, Sanofi, Sumitomo Pharma, and Taisho Pharmaceutical. Yasushi Fukushima has no disclosures to report. Tomotaka Shingaki and Tomonori Oura are full‐time employees of Eli Lilly Japan K.K. and are minor stockholders in Eli Lilly and Company. Wataru Ogawa reports research support, honoraria for lectures, and donations from Sumitomo Pharma; honoraria from Abbott, Boehringer Ingelheim, and Novo Nordisk; and research funding from Boehringer Ingelheim, Eli Lilly and Company, Noster, and Novo Nordisk.
